Author Interviews, Diabetes, JAMA, Kidney Disease / 01.09.2015
Finerenone Reduces Urine Protein Loss in Diabetic Kidney Disease
MedicalResearch.com Interview with:
George L. Bakris MD
Professor of Medicine
Director, Comprehensive Hypertension Center
University of Chicago Medicine
Medical Research: What is the background for this study? What are the main findings?
Dr. Bakris: Aldosterone receptor antagonists such as spironolactone are known to reduce mortality from heart failure and reduce albuminuria, a well-known marker of diabetic kidney disease progression. Finerenone is a novel nonsteroidal aldosterone receptor antagonist and is associated with less hyperkalemia (high blood potassium levels) compared to traditional aldosterone receptor blockers like spironolactone. The current study was a dose finding study to ascertain the optimal dose of finerenone for reducing urine albumin (a key risk marker in people with diabetic kidney disease) that is also associated with the smallest rise in serum potassium. The main findings are that in a dose dependent manner finerenone reduced albuminuria and at the highest dose a modest rise in serum potassium. Finerenone was also very well tolerated.


























